Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

31, 2008. The six month increase is primarily the result of net sales, offset by our repurchase of $45 million principal amount of our senior convertible notes. Cash flow provided by operating activities for the six months ended June 30, 2009 was $15.9 million.

Looking ahead in 2009

ViroPharma is revising its guidance for the year 2009. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following:

  • Net Cinryze sales are expected to be $80 to $95 million.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $135 to $145 million, which includes approximately $18 million of maribavir-related expenses. SFAS 123R expenses are expected to be between $11 and $13 million.

The company is providing Cinryze net sales guidance and withdrawing Vancocin net sales guidance to align the company's guidance with its growth driver and in light of the August 4, 2009 FDA advisory committee regarding proposed bioequivalence recommendations for Vancocin.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on July 29, 2009 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... Dr. Farhad Rafizadeh, specializes in delivering world-class results. ... of Plastic Surgery and a background in art, Dr. ... look. His unique approach to Plastic Surgery involves ... addition, his practice delivers a superior level of comfort ...
(Date:5/28/2015)... 2015 Medelis, Inc., a specialty oncology ... company in the role of president. , “ Bill Taaffe ... CRO industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He ... our next phase of growth.” , Taaffe joined ICON’s ... nine employees to over 4,500 employees, achieving 12 consecutive years ...
(Date:5/28/2015)... May 28, 2015 Boston Celtics Legend ... Beth, both Genesis Foundation Board of Directors members, will ... Celebrity Fishing Tournament June 4-7. For the past 34 ... benefitting The Genesis Foundation for children by bringing together ... , The 34th John Havlicek Celebrity Fishing Tournament will ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Workers’ compensation costs ... typical state, a recent study by the Workers Compensation ... over a three-year period. , The WCRI study, CompScope™ ... which workers missed seven days or more of work with ... the average 2011 Michigan claim was 4 percent lower than ...
(Date:5/28/2015)... Dallas, TX (PRWEB) May 28, 2015 Ticket ... international friendly soccer match between Mexico and Argentina ... teams in the world will compete on the pitch at ... against one another in an international friendly on Tuesday, September ... the most talented nations in the world including some of ...
Breaking Medicine News(10 mins):Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3
... BC, Oct. 15 /PRNewswire/ - Neuromed,Pharmaceuticals, a biopharmaceutical ... today it has successfully reached an,agreement with the ... Protocol Assessment (SPA) process for the planned pivotal ... the treatment of,chronic pain. A SPA is a ...
... Patients with Kidney Impairments - - ... of Patients -, CAMBRIDGE, Mass., Oct. 15 ... announced that the U.S. Food and,Drug Administration (FDA) ... patients with impaired kidney function, including those,requiring dialysis. ...
... LAVAL, QC, Oct. 15 /PRNewswire-FirstCall/ - Labopharm Inc. ... initiated the U.S. Food and Drug,Administration (FDA),s Formal ... Company,s once-daily formulation of,tramadol. Labopharm received a second ... of tramadol in May of this year. The ...
... It has supernatural effects on some diseases, but the ... reported in the November 7 issue of the World ... a Chinese medicinal compound, delisheng, for the therapy of ... was led by Dr. Ke-Jun Nan from The First ...
... over past decade , , MONDAY, Oct. 15 (HealthDay News) -- ... United States, offering what an expert called a "glimmer of ... report, cancer death rates fell by 2.1 percent each year ... annual decline recorded between 1993 and 2003. , "That,s a ...
... Philadelphia, PA, October 15, 2007 Using a ... cancer, epidemiologists and clinical researchers from Memorial Sloan-Kettering ... screening colonoscopy which clears pre-cancerous polyps from the ... Zauber, Ph.D., Sidney J. Winawer, M.D., MACG and ...
Cached Medicine News:Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 2Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 3Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 2Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 3Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 4Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 5Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 6Health News:Labopharm appeals FDA's decision on once-daily tramadol 2Health News:A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma 2Health News:U.S. Cancer Death Rate Continues to Fall 2Health News:U.S. Cancer Death Rate Continues to Fall 3Health News:First colonoscopy with removal of polyps linked to reduction in colon cancer death 2Health News:First colonoscopy with removal of polyps linked to reduction in colon cancer death 3
(Date:5/28/2015)... Mass., May 28, 2015  Shareholder rights law ... whether certain officers and directors of Eleven Biotherapeutics, ... Eleven Biotherapeutics is a clinical-stage biopharmaceutical company that ... therapeutics to treat eye diseases, primarily in ... View this press release on the law ...
(Date:5/28/2015)... 28, 2015   Eli Lilly and Company (NYSE: ... host a webcast on June 11 to discuss data from ... rheumatoid arthritis. Data from these two trials, RA-BEACON and RA-BUILD, will ... the EULAR Congress 2015 in Rome, Italy ... to11:00 a.m. Eastern Daylight Time. The live audio webcast can ...
(Date:5/28/2015)... ROCKLAND, Mass. , May 28, 2015 /PRNewswire/ ... a leading company for innovative and top-quality high-tech ... today announced a global collaboration agreement with the ... dedicated to advancing fertility science and helping couples ... Germany , a global market ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 2Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 3Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 4
... SuccessEHS, a nationally recognized, streamlined practice management and ... recently named by the Arkansas Regional Extension Center (REC) ... health care initiatives. Regional Extension ... endowed by the Office of the National Coordinator for ...
... 17, 2011 ORTHOCON, Inc., a developer of implantable products ... to bone, today announced the U.S. launch of its first ... The HEMA SORB Absorbable Bone Hemostat ... absorbable putty that is designed to rapidly stop bleeding when ...
Cached Medicine Technology:Arkansas REC Selects SuccessEHS as Preferred Vendor 2Arkansas REC Selects SuccessEHS as Preferred Vendor 3ORTHOCON® Announces U.S. Market Launch of HEMASORB® 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: